Brilinta倍林達

Brilinta Use In Pregnancy & Lactation

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Use In Pregnancy & Lactation
Women of childbearing potential: Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during Brilinta therapy.
Pregnancy: There are no or limited amount of data from the use of ticagrelor in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Ticagrelor is not recommended during pregnancy.
Breastfeeding: Available pharmacodynamic/toxicological data in animals have shown excretion of ticagrelor and its active metabolites in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Brilinta therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Fertility: Ticagrelor had no effect on male or female fertility in animals (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in